The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2026 | PTCy, frailty, and cardiomyopathy: a challenging triad in modern allogeneic transplantation
In this video, María Queralt Salas, MD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses the challenging triad of post-transplant cyclophosphamide (PTCy), frailty, and cardiomyopathy in modern allogeneic stem cell transplantation, highlighting the need to assess patient frailty and implement prehabilitation and rehabilitation programs to mitigate the risks associated with this triad. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, I think the use of PTCy-based prophylaxis is being expanded in transplant settings and it’s one of the GVHD prophylaxis that we must use in our contexts. In addition, we are transplanting older patients and frail patients who are at risk of presenting with cardiac complications and PTCy increases the risk for these events. So the combination of this triad is difficult to manage...
Well, I think the use of PTCy-based prophylaxis is being expanded in transplant settings and it’s one of the GVHD prophylaxis that we must use in our contexts. In addition, we are transplanting older patients and frail patients who are at risk of presenting with cardiac complications and PTCy increases the risk for these events. So the combination of this triad is difficult to manage. My proposal is that we should assess the frailty of patients and try to implement prehabilitation and rehabilitation programs to help them to cope with the transplant and explore how if we reduce PTCy doses, how we can decrease the risk of cardiac toxicity in this context.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
